The Melbourne firm helped a biopharmaceutical firm debut on the ASX and a German company acquire a company in Australia
The firm advised Telix Pharmaceuticals on its $50m IPO, which was fully underwritten by Taylor Collison and Wilsons Corporate Finance. The biopharmaceutical company, which develops diagnostic and therapeutic products for the treatment of cancer, debuted on the ASX under the TLX ticker.
Clarendons previously acted for Telix on its seed financing round, pipeline acquisition, and commercial partnerships.
The firm’s team was led by directors Alex Bean and Nick Golding, who were supported by lawyer Natasha Arora and graduates Rachel Morris and Stephen Dyason.
Clarendons also acted for OPED AG in its acquisition of oapl, Australia’s leading provider of specialised orthotic and prosthetic services. The deal, which was for an undisclosed amount, also included oapl Bendigo and oapl Fremantle Orthotic Services.
OPED was founded in Germany and has operations in Australia, Germany, Switzerland, the UK, and the US. The acquisition grows OPED’s portfolio, while giving oapl a global distribution footprint.
The Clarendons team was led by director Nick Manuell, who was supported by lawyers Ingrid Mohr and Natasha Arora.
Specialist firm snags partner from global giant
Japanese paper behemoth buys Australian business with help from two firms